Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Harnessing the biocatalytic potential of iron- and α-ketoglutarate-dependent dioxygenases in natural product total synthesis.

Zwick CR 3rd, Renata H.

Nat Prod Rep. 2020 Feb 14. doi: 10.1039/c9np00075e. [Epub ahead of print] Review.

PMID:
32055818
2.

Characterization of a Citrulline 4-Hydroxylase from Nonribosomal Peptide GE81112 Biosynthesis and Engineering of Its Substrate Specificity for the Chemoenzymatic Synthesis of Enduracididine.

Zwick CR 3rd, Sosa MB, Renata H.

Angew Chem Int Ed Engl. 2019 Dec 19;58(52):18854-18858. doi: 10.1002/anie.201910659. Epub 2019 Nov 11.

PMID:
31610076
3.

Fraternal twins: distinction between PbPc and SnPc by their switching behaviour in a scanning tunnelling microscope.

Forker R, Gruenewald M, Sojka F, Peuker J, Mueller P, Zwick C, Huempfner T, Meissner M, Fritz T.

J Phys Condens Matter. 2019 Apr 3;31(13):134004. doi: 10.1088/1361-648X/aafeae.

PMID:
30729922
4.

Movement Speed Estimation Based on Foot Acceleration Patterns.

Grad S, Zrenner M, Schuldhaus D, Wirth M, Cegielny T, Zwick C, Eskofier BM.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:3505-3508. doi: 10.1109/EMBC.2018.8513042.

PMID:
30441134
5.

Oxidopyrylium-Alkene [5 + 2] Cycloaddition Conjugate Addition Cascade (C3) Sequences: Scope, Limitation, and Computational Investigations.

Kaufman RH, Law CM, Simanis JA, Woodall EL, Zwick CR 3rd, Wedler HB, Wendelboe P, Hamaker CG, Goodell JR, Tantillo DJ, Mitchell TA.

J Org Chem. 2018 Sep 7;83(17):9818-9838. doi: 10.1021/acs.joc.8b01322. Epub 2018 Jul 26.

PMID:
30001484
6.

Evolution of Biocatalytic and Chemocatalytic C-H Functionalization Strategy in the Synthesis of Manzacidin C.

Zwick CR 3rd, Renata H.

J Org Chem. 2018 Jul 20;83(14):7407-7415. doi: 10.1021/acs.joc.8b00248. Epub 2018 May 24.

PMID:
29771530
7.

Remote C-H Hydroxylation by an α-Ketoglutarate-Dependent Dioxygenase Enables Efficient Chemoenzymatic Synthesis of Manzacidin C and Proline Analogs.

Zwick CR 3rd, Renata H.

J Am Chem Soc. 2018 Jan 24;140(3):1165-1169. doi: 10.1021/jacs.7b12918. Epub 2018 Jan 16.

PMID:
29283572
8.

Applications of Oxygenases in the Chemoenzymatic Total Synthesis of Complex Natural Products.

King-Smith E, Zwick CR 3rd, Renata H.

Biochemistry. 2018 Jan 30;57(4):403-412. doi: 10.1021/acs.biochem.7b00998. Epub 2017 Nov 29. Review.

PMID:
29140086
9.

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.

Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hünerlitürkoglu AN, Schmitz N, Pöschel V, Rixecker T, Berdel C, Rübe C, Held G, Zwick C.

Br J Haematol. 2017 Nov;179(3):410-420. doi: 10.1111/bjh.14860. Epub 2017 Oct 8.

PMID:
28990173
10.

Fully Atomistic Understanding of the Electronic and Optical Properties of a Prototypical Doped Charge-Transfer Interface.

Baby A, Gruenewald M, Zwick C, Otto F, Forker R, van Straaten G, Franke M, Stadtmüller B, Kumpf C, Brivio GP, Fratesi G, Fritz T, Zojer E.

ACS Nano. 2017 Oct 24;11(10):10495-10508. doi: 10.1021/acsnano.7b05828. Epub 2017 Sep 21.

11.

Atypical Proliferative (Borderline) Serous Tumor in the Brain: A Case Report.

Xing D, Jenson EG, Zwick CA, Rodriguez FJ, Kurman RJ.

Int J Gynecol Pathol. 2018 Jan;37(1):52-56. doi: 10.1097/PGP.0000000000000389.

PMID:
28700421
12.

Complex Stoichiometry-Dependent Reordering of 3,4,9,10-Perylenetetracarboxylic Dianhydride on Ag(111) upon K Intercalation.

Zwick C, Baby A, Gruenewald M, Verwüster E, Hofmann OT, Forker R, Fratesi G, Brivio GP, Zojer E, Fritz T.

ACS Nano. 2016 Feb 23;10(2):2365-74. doi: 10.1021/acsnano.5b07145. Epub 2016 Jan 26.

13.

CD4⁺ T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström's macroglobulinemia.

Neumann F, Pfreundschuh M, Preuss KD, Schormann C, Zwick C, Murawski N, Kubuschok B.

Int J Cancer. 2015 Sep 1;137(5):1076-84. doi: 10.1002/ijc.29478. Epub 2015 Feb 26.

14.

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N.

J Clin Oncol. 2014 Dec 20;32(36):4127-33. doi: 10.1200/JCO.2013.54.6861. Epub 2014 Nov 17. Erratum in: J Clin Oncol. 2015 Jun 10;33(17):1991.

PMID:
25403207
15.

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.

Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hänel M, Witzens-Harig M, Mahlberg R, Rübe C, Fleckenstein J, Zwick C, Glass B, Schmitz N, Zeynalova S, Pfreundschuh M.

Blood. 2014 Jul 31;124(5):720-8. doi: 10.1182/blood-2013-10-535021. Epub 2014 Jun 17.

PMID:
24939657
16.

Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.

Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C.

Ann Oncol. 2014 Sep;25(9):1800-6. doi: 10.1093/annonc/mdu208. Epub 2014 Jun 13.

17.

Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.

Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, Bittenbring J, Hänel M, Wilhelm S, Schubert J, Schmitz N, Löffler M, Rübe C, Pfreundschuh M.

J Clin Oncol. 2014 Apr 10;32(11):1112-8. doi: 10.1200/JCO.2013.51.4505. Epub 2014 Feb 3.

PMID:
24493716
18.

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.

Hohloch K, Zwick C, Ziepert M, Hasenclever D, Kaiser U, Engert A, Höffkes HG, Kroschinsky F, Mesters R, Feller AC, Löffler M, Trümper L, Pfreundschuh M; German High-Grade Non-Hodgkin´s Lymphoma Study Group (DSHNHL).

Springerplus. 2014 Jan 3;3:5. doi: 10.1186/2193-1801-3-5. eCollection 2014 Jan 3.

19.

Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS/MM.

Zwick C, Held G, Auth M, Bernal-Mizrachi L, Roback JD, Sunay S, Iida S, Kuroda Y, Sakai A, Ziepert M, Ueda R, Pfreundschuh M, Preuss KD.

Int J Cancer. 2014 Aug 15;135(4):934-8. doi: 10.1002/ijc.28731. Epub 2014 Feb 4.

20.

Suboptimal dosing of rituximab in male and female patients with DLBCL.

Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, Rixecker T, Poeschel V, Zwick C, Reiser M, Schmitz N, Murawski N.

Blood. 2014 Jan 30;123(5):640-6. doi: 10.1182/blood-2013-07-517037. Epub 2013 Dec 2.

PMID:
24297867
21.

Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement.

Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, Rübe C, Zwick C, Glass B, Schmitz N, Pfreundschuh M.

J Clin Oncol. 2013 Nov 10;31(32):4115-22. doi: 10.1200/JCO.2012.48.0467. Epub 2013 Sep 23.

PMID:
24062391
22.

Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma.

Zeynalova S, Ziepert M, Scholz M, Schirm S, Zwick C, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Ann Hematol. 2013 Dec;92(12):1641-52. doi: 10.1007/s00277-013-1842-x. Epub 2013 Jul 28.

PMID:
23892922
23.

To tilt or not to tilt: correction of the distortion caused by inclined sample surfaces in low-energy electron diffraction.

Sojka F, Meissner M, Zwick C, Forker R, Vyshnepolsky M, Klein C, Horn-von Hoegen M, Fritz T.

Ultramicroscopy. 2013 Oct;133:35-40. doi: 10.1016/j.ultramic.2013.04.005. Epub 2013 Apr 29.

PMID:
23770540
24.

EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.

Neumann F, Kaddu-Mulindwa D, Widmann T, Preuss KD, Held G, Zwick C, Roemer K, Pfreundschuh M, Kubuschok B.

Cancer Immunol Immunother. 2013 Jul;62(7):1211-22. doi: 10.1007/s00262-013-1412-z. Epub 2013 Apr 26.

PMID:
23619976
25.

Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells.

Zwick C, Fadle N, Regitz E, Kemele M, Stilgenbauer S, Bühler A, Pfreundschuh M, Preuss KD.

Blood. 2013 Jun 6;121(23):4708-17. doi: 10.1182/blood-2012-08-447904. Epub 2013 Apr 11.

PMID:
23580660
26.

Determination and correction of distortions and systematic errors in low-energy electron diffraction.

Sojka F, Meissner M, Zwick C, Forker R, Fritz T.

Rev Sci Instrum. 2013 Jan;84(1):015111. doi: 10.1063/1.4774110.

PMID:
23387699
27.

Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.

Kubuschok B, Pfreundschuh M, Breit R, Hartmann F, Sester M, Gärtner B, König J, Murawski N, Held G, Zwick C, Neumann F.

Hum Gene Ther. 2012 Dec;23(12):1224-36. doi: 10.1089/hum.2011.153. Epub 2012 Oct 31.

PMID:
22966960
28.

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

Müller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M.

Blood. 2012 Apr 5;119(14):3276-84. doi: 10.1182/blood-2011-09-380949. Epub 2012 Feb 15.

PMID:
22337718
29.

Fourteen-day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP-14): use it right or do not use it at all.

Zwick C, Pfreundschuh M.

Leuk Lymphoma. 2012 May;53(5):758-9. doi: 10.3109/10428194.2011.647316. Epub 2012 Feb 13. No abstract available.

PMID:
22263568
30.

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.

Zwick C, Hartmann F, Zeynalova S, Pöschel V, Nickenig C, Reiser M, Lengfelder E, Peter N, Schlimok G, Schubert J, Schmitz N, Loeffler M, Pfreundschuh M; German High-Grade Non-Hodgkin Lymphoma Study Group.

Ann Oncol. 2011 Aug;22(8):1872-7. doi: 10.1093/annonc/mdq674. Epub 2011 Feb 3.

31.

Current concepts in the classification, diagnosis and treatment of vascular anomalies.

Ernemann U, Kramer U, Miller S, Bisdas S, Rebmann H, Breuninger H, Zwick C, Hoffmann J.

Eur J Radiol. 2010 Jul;75(1):2-11. doi: 10.1016/j.ejrad.2010.04.009. Epub 2010 May 13.

PMID:
20466500
32.

Rituximab in high-grade lymphoma.

Zwick C, Murawski N, Pfreundschuh M; German High-Grade Non-Hodgkin Lymphoma Study Group.

Semin Hematol. 2010 Apr;47(2):148-55. doi: 10.1053/j.seminhematol.2010.01.008. Review.

PMID:
20350662
33.

Unresolved issues in diffuse large B-cell lymphomas.

Murawski N, Zwick C, Pfreundschuh M.

Expert Rev Anticancer Ther. 2010 Mar;10(3):387-402. doi: 10.1586/era.09.170. Review.

PMID:
20214520
34.

Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens.

Zwick C, Preuss KD, Kubuschok B, Held G, Ahlgrimm M, Bittenbring J, Schubert J, Neumann F, Pfreundschuh M.

Ann Hematol. 2009 Oct;88(10):999-1003. doi: 10.1007/s00277-009-0711-0. Epub 2009 Feb 24.

PMID:
19238384
35.

Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas.

Zwick C, Held G, Hammermeister V, Alahmad A, Kubuschok B, Bittenbring J, Ahlgrimm M, Neumann F, Preuss KD, Pfreundschuh M.

J Cancer Res Clin Oncol. 2009 Sep;135(9):1207-13. doi: 10.1007/s00432-009-0561-0. Epub 2009 Feb 21.

PMID:
19234720
36.

[Treatment of diffuse large B-cell lymphoma].

Gleissner B, Zwick C, Pfreundschuh M.

Dtsch Med Wochenschr. 2008 Sep;133(36):1785-94; quiz 1795-6. doi: 10.1055/s-0028-1082813. Epub 2008 Sep 2. Review. German.

PMID:
18767006
37.

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).

Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, Hensel M, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M; German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL).

Ann Hematol. 2008 Sep;87(9):717-26. doi: 10.1007/s00277-008-0500-1. Epub 2008 Jun 28.

PMID:
18587579
38.

Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma.

Zwick C, Gleissner B, Pfreundschuh M.

Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 2:S43-9. Review.

PMID:
18284715
39.

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.

Trümper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2008 Mar;19(3):538-44. doi: 10.1093/annonc/mdm497. Epub 2008 Jan 22.

40.

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Pfreundschuh M, Zwick C, Zeynalova S, Dührsen U, Pflüger KH, Vrieling T, Mesters R, Mergenthaler HG, Einsele H, Bentz M, Lengfelder E, Trümper L, Rübe C, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2008 Mar;19(3):545-52. Epub 2007 Dec 6.

41.

MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.

Held G, Wadle A, Dauth N, Stewart-Jones G, Sturm C, Thiel M, Zwick C, Dieckmann D, Schuler G, Hoogenboom HR, Lévy F, Cerundolo V, Pfreundschuh M, Renner C.

Eur J Immunol. 2007 Jul;37(7):2008-17. Erratum in: Eur J Immunol. 2008 May;38(5):1465-6.

42.

[Treatment of aggressive lymphomas].

Gleissner B, Zwick C, Pfreundschuh M.

Internist (Berl). 2007 Apr;48(4):389-95. Review. German.

PMID:
17361405
43.

Serological immune response to cancer testis antigens in patients with pancreatic cancer.

Wadle A, Kubuschok B, Imig J, Wuellner B, Wittig C, Zwick C, Mischo A, Waetzig K, Romeike BF, Lindemann W, Schilling M, Pfreundschuh M, Renner C.

Int J Cancer. 2006 Jul 1;119(1):117-25.

44.

[Soft-tissue coverage of the hand using the posterior interosseous artery flap].

Zwick C, Schmidt G, Rennekampff HO, Schaller HE.

Handchir Mikrochir Plast Chir. 2005 Jun;37(3):179-85. German.

PMID:
15997429
45.

Analysis of the B-cell repertoire against antigens expressed by human neoplasms.

Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M.

Immunol Rev. 2002 Oct;188:43-50. Review.

PMID:
12445280
46.

A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing.

Türeci O, Sahin U, Koslowski M, Buss B, Bell C, Ballweber P, Zwick C, Eberle T, Zuber M, Villena-Heinsen C, Seitz G, Pfreundschuh M.

Oncogene. 2002 May 30;21(24):3879-88.

47.

Expression of cancer testis genes in human brain tumors.

Sahin U, Koslowski M, Türeci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W, Pfreundschuh M.

Clin Cancer Res. 2000 Oct;6(10):3916-22.

48.

Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens.

Türeci O, Sahin U, Zwick C, Neumann F, Pfreundschuh M.

Hybridoma. 1999 Feb;18(1):23-8.

PMID:
10211784
49.

Expression of SSX genes in human tumors.

Türeci O, Chen YT, Sahin U, Güre AO, Zwick C, Villena C, Tsang S, Seitz G, Old LJ, Pfreundschuh M.

Int J Cancer. 1998 Jul 3;77(1):19-23.

50.

Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens.

Türeci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M.

Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5211-6.

Supplemental Content

Support Center